Hemodynamic Profile of Patients With Heart Failure and Preserved Ejection Fraction Vary by Age

Shane Nanayakkara, MD; Mark Haykowsky, PhD; Justin Mariani, MD, PhD; Vanessa Van Empel, MD, PhD; Micha T. Maeder, MD, PhD; Donna Vizi, RN; David M. Kaye, MD, PhD

Background—Patients with heart failure with preserved ejection fraction (HFpEF) exhibit a range of cardiovascular phenotypic profiles modified by several common comorbidities. In particular, patients with HFpEF tend to be older; however, it is unclear whether the effects of cardiovascular aging per se modify the expression of HFpEF. We therefore sought to investigate the interaction between age and physiologic profile in patients with HFpEF.

Methods and Results—We assessed the hemodynamic and metabolic profile of 40 patients with HFpEF. Patients underwent right heart catheterization at rest and during supine cycle ergometry, and were segregated into 2 groups by the median age of the cohort. Older patients with HFpEF demonstrated reduced resting cardiac output (4.8±1.2 L/min versus 5.7±1.1 L/min). With exercise, older patients demonstrated a marked rise in arteriovenous oxygen content difference (10.8±1.8 versus 7.9±2.4 ml, \( P \leq 0.001 \)), driven by enhanced oxygen extraction. There was no significant difference in peak pulmonary capillary wedge pressure (30±7 mm Hg versus 27±6, \( P = 0.135 \)), including when indexed to workload (pulmonary capillary wedge pressure/W, 0.88 mm Hg/W versus 0.92; \( P = 0.83 \)).

Conclusions—Older patients with HFpEF display a different physiological phenotype compared with younger patients, with enhanced oxygen extraction and lower increment in cardiac output to increase oxygen consumption from rest to peak supine exercise. This finding highlights the importance in considering age when considering therapeutic options in patients with HFpEF. (∗Am Heart Assoc. 2017;6:e005434. DOI: 10.1161/JAHA.116.005434.)

Key Words: aging • geriatrics • heart failure with preserved ejection fraction • hemodynamics • oxygen extraction
Clinical Perspective

What Is New?

- Heart failure with preserved ejection fraction accounts for half of all cases of heart failure and predominantly occurs in the older population.
- There is significant heterogeneity in patients with heart failure with preserved ejection fraction.
- This exercise hemodynamic study demonstrates that older patients with heart failure with preserved ejection fraction have a different physiological phenotype compared with younger patients.

What Are the Clinical Implications?

- Understanding subtypes of heart failure with preserved ejection fraction is critical to appropriately targeting therapy.
- The differing physiological limitation to exercise across the spectrum of age may lead to different foci of therapy, such as exercise therapy for the periphery versus pharmacological therapy targeting filling pressures or cardiac output.

who satisfied criteria outlined by the European Society of Cardiology guidelines for the diagnosis of HFrEF<sup>11</sup> were included. Study protocols were approved by human research ethics committee of The Alfred Hospital and informed written consent was obtained from all participants.

Catheterization and Exercise Protocol

Following informed consent, patients underwent standard right heart catheterization using a 7F sheath from the brachial or jugular venous approach. A 3F arterial sheath was inserted into the radial artery for arterial blood sampling. No medication changes were made before catheterization and tests were performed in the unfasted state. At rest, end-expiratory measurements were taken from the right atrium, right ventricle, pulmonary artery, and pulmonary capillary wedge position. Symptom-limited (leg fatigue and/or dysnea) exercise was performed using supine cycle ergometry at a cadence of 60 revolutions per minute, with a graded increase in resistance every 3 minutes to a maximum of 1.5 W/kg. Repeated hemodynamic measurements were taken at peak exercise from the wedge position and pulmonary artery. During exercise, pressures were recorded at the end of expiration. Mixed venous blood gas samples were taken at rest and at peak exercise from the pulmonary artery following discarding of 5 mL of blood. Arterial blood pressure (BP) was obtained by direct measurement via the radial arterial sheath. Cardiac output (CO) at rest was measured via thermodilution as an average of ≥3 measurements at rest and a single measurement was taken at each stage of exercise and indexed to body surface area (cardiac index). Oxygen consumption (VO<sub>2</sub>) was calculated using the Fick equation based on arterial and mixed venous samples at rest and during exercise and hemoglobin and CO at rest and during exercise. Oxygen delivery was calculated as the product of the arterial oxygen content and CO. The oxygen extraction ratio (O<sub>2</sub>ER) is the quotient of VO<sub>2</sub> divided by the oxygen delivery, presented as a percentage.

Statistical Analysis

Continuous variables are reported as mean±SD. Between-group differences were compared by Student t test. The correlation between age and hemodynamic and metabolic variables was analyzed using the Pearson correlation coefficient. Statistical analysis was performed with SPSS 23 (IBM Corp). Missing data were excluded from analysis (<5% of overall data, from specific subanalyses only).

Patient Characteristics

The mean age of the study cohort was 68 years. To compare the rest and exercise hemodynamic profiles of younger and older patients with HFrEF, the study group was separated by the group median. The younger group (n=21) had a mean age of 62±8 years and the older group (n=19) had a mean age of 75±5 years. The baseline demographics and resting hemodynamics of the study population are presented in Table 1. Body mass index was slightly higher in the younger age group; however, this was not statistically significant (32.1±6.3 versus 29.5±3.8, P=0.14). There were more women within the younger group, but there was no significant difference in mean age between sexes.

Resting Hemodynamics

Resting heart rate, mean pulmonary artery pressure, and mean pulmonary capillary wedge pressure were similar between groups (Table 1). Systolic BP was significantly higher in the older patients while the mean arterial BP was similar between the 2 groups. Cardiac index was significantly lower at baseline in older patients with HFrEF.

Exercise Hemodynamics

Peak power output, VO<sub>2</sub>, heart rate, systolic BP, mean pulmonary artery pressure, pulmonary capillary wedge position, and systemic vascular resistance were not significantly different between groups. Peak arterial venous oxygen difference (AVO<sub>2</sub>Diff) and O<sub>2</sub>ER were significantly higher, while venous O<sub>2</sub> saturation was significantly lower in older compared with younger patients with HFrEF (Table 2).
The results of Pearson correlation between age and hemodynamic and metabolic variables are shown in Table 3. There was a modest relationship with decreasing body mass index ($r=0.39$, $P=0.01$). At rest, systolic BP, systemic vascular resistance, AVO$_2$Diff, and O$_2$ER were all positively correlated, while there was an inverse association with CO. With exercise, there was an increase in mean exercise pulmonary capillary wedge position with increasing age ($r=0.35$, $P=0.03$), with a stronger relationship with AVO$_2$Diff ($r=0.44$, $P=0.006$) and O$_2$ER ($r=0.48$, $P=0.002$). There was no significant correlation with CO ($r=-0.25$, $P=0.12$).

The major new finding of this study is that the determinants of physical limitation in patients with HFP EF differ according to age. This finding has important implications for the development of targeted therapies. Specifically, while younger and older patients with HFP EF increased their VO$_2$ to similar degrees during exertion, the physiologic determinants were different across the groups. In particular, older patients with HFP EF were reliant upon O$_2$ER to a greater degree.

Adequate delivery of oxygen to the active muscles is essential for aerobic activity. Convective O$_2$ delivery is dependent on multiple factors, including adequate pulmonary oxygenation, normal oxygen-carrying capacity, hemoglobin, and CO. Peripheral O$_2$ extraction is directly proportionate to delivery and inversely related to muscle blood flow. Moreover, abnormal skeletal morphology (decreased oxidative muscle fibers, capillarity oxidative metabolism, and mitochondrial function) may also play an important role in
Bhella and colleagues\textsuperscript{16} found that the lower VO\textsubscript{2} during peak exercise testing. In 104 patients with HFpEF (mean age 63 years), Abudiab et al\textsuperscript{23} performed symptom-limited exercise hemodynamic assessment in 109 patients with HFpEF compared with controls, and determined that CO reserve limitation was the primary limitation to exercise; however, AVO\textsubscript{2}Diff indexed to VO\textsubscript{2} was higher in patients with HFpEF compared with controls, and was a primary predictor of peak VO\textsubscript{2}. In 40% of patients, impaired peripheral extraction was the predominant limiting factor to exercise capacity.

We confirm and extend these findings by demonstrating that the increased VO\textsubscript{2} from rest to peak supine exercise in older patients (mean age 75 years) with HFpEF is caused by increased oxygen delivery and concomitant increase in O\textsubscript{2}ER (decreased mixed venous O\textsubscript{2} saturation). The mechanisms responsible for the increased O\textsubscript{2}ER were not examined in this study; however, they may be caused by a greater transit time for O\textsubscript{2} to be extracted by the active muscles as a result of a lower CO (and muscle blood flow) compared with younger patients with HFpEF. The ability to augment CO did not differ between groups, which may suggest that VO\textsubscript{2} is dependent on factors not dependent on flow, such as muscle wasting. That DO\textsubscript{2} was 40% higher in older compared with younger patients with HFpEF may suggest differences in capillarity, and diffusion distance may differ between groups, although we cannot definitively prove these findings.\textsuperscript{20}

Studies have identified a range of abnormalities in parameters of both central cardiovascular performance and peripherally in relation to vascular and skeletal muscle structure and function. Central hemodynamic limitations include impaired diastolic function, chronotropic incompetence, abnormal right ventricular-pulmonary artery coupling,\textsuperscript{21} and vasodilator reserve. Age is a powerful nonmodifiable risk factor for the development of HFpEF and plays a fundamental role in passive and active relaxation properties. Aging is associated with myocardial fibrosis, transforming growth factor-\(\beta\) activation, myocardial stiffness through hypophosphorylation of titin, and impaired calcium signaling.\textsuperscript{8} Population-based studies demonstrate that age is a significant predictive factor of the development of diastolic dysfunction, even in individuals without apparent cardiovascular disease. Similarly, age was predictive of the development of incident heart failure.\textsuperscript{5,22} These changes with increasing age may reduce CO, particularly with exertion, and compensatory mechanisms develop to enhance oxygen extraction to maintain the same VO\textsubscript{2}. Indeed, we found that AVO\textsubscript{2}Diff was positively related (\(r=0.44, P=0.006\)) and mixed venous O\textsubscript{2} saturation was inversely related to age in patients with HFpEF.

Previous studies have examined CO response to exercise in patients with HFpEF. Currently, only one invasive study has measured AVO\textsubscript{2}Diff during maximal exercise with a similar power output to our study (40 W) in older patients with HFpEF (mean age 67 years). Abudiab et al\textsuperscript{23} performed symptom-limited exercise hemodynamic assessment in 109 patients with HFpEF compared with controls, and determined that CO reserve limitation was the primary limitation to exercise; however, AVO\textsubscript{2}Diff indexed to VO\textsubscript{2} was higher in patients with HFpEF, again supporting peripheral adaptation to the impairment in oxygen delivery. Notably, the peak AVO\textsubscript{2}Diff of the patients with HFpEF and controls were not significantly different.
different (9.9 and 10.1 mL/dL, respectively), similar to the value we found in our older patients with HFpEF. Moreover, our rest-to-peak exercise change in AVO2Diff (5.7 mL/dL) is similar to that reported by Abudiab et al (5.2 mL/dL).

The failure of previous trials of therapy in HFpEF to produce positive results has been attributed to the heterogeneity of the population and as such phenotypic classification has been developed to target therapy more effectively. Such models have included variables such as hypertension, obesity, coronary artery disease, and renal dysfunction. Shah et al prospectively analyzed 397 patients with HFpEF for phenotype classification using clinical characteristics, natriuretic peptide values, and echocardiographic data. Using cluster analysis, 3 groups were identified, with the oldest group at highest risk for adverse outcomes, with the highest pulmonary pressures (both mean pulmonary artery pressure and pulmonary capillary wedge position) and worst right ventricular function. This novel study did not include exercise hemodynamics, however, and no physiological parameters of oxygen extraction were assessed. Including these parameters may lead to an improved understanding of the physiologic separation between these subtypes, or identify new phenotypes, permitting the use of targeted therapy. Importantly, the study highlights the concept that HFpEF describes a collection of disease pathologies culminating in the syndrome of heart failure, and careful dissection of the various contributing components is critical to offering the appropriate therapy. Exercise testing may be useful to phenotype the predominant limitation to exercise to guide future trials and treatment. Given that older individuals have reduced muscle mass, coupled with the finding that resistance can increase muscle mass and capillarity, we believe that older patients with HFpEF may benefit from resistance training. Consistent with this finding, Pu et al found that resistance training increases aerobic endurance, type I (oxidative) myosin heavy chain, and citrate synthase activity in older patients (77 years) with heart failure with reduced ejection fraction. In this study, we demonstrate that across age groups, exercise testing in patients with HFpEF demonstrates different mechanisms to attain the same VO2. Future therapies will need to take into account age and exercise hemodynamic parameters to target therapy appropriately.

Strengths and Limitations

This study differs from previous trials in several ways. First, VO2 was calculated rather than using expired gas analysis. Second, the analysis was performed between patients with HFpEF, rather than comparing physiology with that of healthy controls. Objective quantification of physiologic peak using peak respiratory exchange ratio or lactate was not recorded, and patients exercised to symptom-limited maximum. The small group sizes increase the chance of type II error, and larger group sizes may yield a difference in CO. Echocardiographic data during rest and exercise were not available for all participants, and, as such, accurate quantification of left ventricular end-diastolic volume through direct visualization and echocardiographic parameters of diastolic dysfunction such as E/e’ were not available. Similarly, left ventricular wall thickness and left ventricular mass were not recorded at the time of cardiac catheterization. As a retrospective study, further delineation of the relative contributions to exercise of both CO and peripheral oxygen extraction could not be performed, and although workload matching was not part of the initial protocol, all groups performed a similar level of exercise. Notably, the youngest cohort of patients attained a lower peak VO2, perhaps limited by volitional exhaustion, although this could not be analyzed retrospectively. Finally, the study did not directly assess peripheral blood flow or arterial endothelial dysfunction, which have been implicated in the pathogenesis of HFpEF and may be responsible for the impaired peripheral reserve in younger patients.

Conclusions

With increasing age, patients with HFpEF demonstrate evidence of enhanced peripheral oxygen extraction. Older patients improve arteriovenous oxygen difference through enhanced peripheral oxygen extraction to maintain equivalent peak VO2 to younger patients. This study highlights the difference in central versus peripheral factors across the spectrum of age in patients with HFpEF.

Sources of Funding

Dr Nanayakkara is supported by a scholarship from the National Heart Foundation of Australia. Dr Haykowsky’s research is supported by the Moritz Chair in Geriatrics at the College of Nursing and Health Innovation at the University of Texas, and the National Institute of Nursing Research of the National Institutes of Health (R15NR016826).

Disclosures

None.

References

1. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006;355:251–259.
2. Mentz RJ, Kelly JP, Von Lueder TG, Voors AA, Lam CSP, Cowie MR, Kjeldsen K, Jankowska EA, Atar D, Butler J, Fuzat M, Zannad F, Pitt B, O’Connor CM. Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction. J Am Coll Cardiol. 2014;64:2281–2293.
3. Oktay AA, Rich JD, Shah SJ. The emerging epidemic of heart failure with preserved ejection fraction. Curr Heart Fail Rep. 2013;10:401–410.
4. Redfield MM, Jacobsen SJ, Burnett JC Jr, Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community. JAMA. 2003;289:194.

5. Kane GC, Karon BL, Mahoney DW, Redfield MM, Roger VL, Burnett JC, Jacobsen SJ, Rodeheffer RJ. Progression of left ventricular diastolic dysfunction and risk of heart failure. JAMA. 2011;306:856–863.

6. Shah SJ, Kitzman DW, Borlaug BA, van Heerebeek L, Zile MR, Kass DA, Paulus WJ. Phenotype-specific treatment of heart failure with preserved ejection fraction. Circulation. 2016;134:73–90.

7. Maurer MS, Mancini D. HfPEF: is splitting into distinct phenotypes by comorbidities the pathway forward? J Am Coll Cardiol. 2014;64:550–552.

8. Loffredo FS, Nikolova AP, Pancoast JR, Lee RT. Heart failure with preserved ejection fraction: molecular pathways of the aging myocardium. Circ Res. 2014;115:97–107.

9. Haykowsky MJ, Herrington DM, Brubaker PH, Morgan TM, Hundley WG, Kitzman DW. Relationship of flow-mediated arterial dilation and exercise capacity in older patients with heart failure and preserved ejection fraction. J Gerontol A Biol Sci Med Sci. 2013;68:161–167.

10. Lexell J. Human aging, muscle mass, and fiber type composition. J Gerontol A Biol Sci Med Sci. 1995;50 Spec No:11–16.

11. Paulus WJ, Tschöpe C, Sanderson JE, Rusconi C, Flachskampf FA, Rademakers FE, Marino P, Smiseth OA, De Keulenaer G, Leite-Moreira AF, Borbély A, Édes I, Handoko ML, Heymans S, Pizzali N, Pieske BM, Dickstein K, Fraser AG, Brutsaert DL. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J. 2007;28:2539–2550.

12. Wagner PD. Determinants of maximal oxygen transport and utilization. Annu Rev Physiol. 1996;58:21–50.

13. Maréchaux S, Samson R, van Belle E, Breyne J, de Monte J, Deldrére C, Chebai N, Menet A, Banfi C, Bouabdallaoui N, le Jemtel TH, Ennezat P-VV. Vascular and microvascular endothelial function in heart failure with preserved ejection fraction. J Card Fail. 2015;22:3–11.

14. Mohammed SF, Hussain S, Mironov SA, Edwards WD, Maleszewski JJ, Redfield MM. Coronary microvascular rarefaction and myocardial fibrosis in heart failure with preserved ejection fraction. Circulation. 2015;131:550–559.

15. Sarma S, Levine BD. Soothing the sleeping giant: improving skeletal muscle oxygen kinetics and exercise intolerance in HfPEF. J Appl Physiol. 2015;119:734–738.

16. Bhella PS, Prasad A, Heinicke K, Hastings JL, Arbab-Zadeh A, Adams-Huet B, Pacini EL, Shibata S, Palmer MD, Newcomer BR, Levine BD. Abnormal haemodynamic response to exercise in heart failure with preserved ejection fraction. Eur J Heart Fail. 2011;13:1296–1304.

17. Molina AJ, Bharadwaj MS, Van Horn C, Nicklas BJ, Lyles MF, Egggebeen J, Haykowsky MJ, Brubaker PH, Kitzman DW. Skeletal muscle mitochondrial content, oxidative capacity, and Mfn2 expression are reduced in older patients with heart failure and preserved ejection fraction and are related to exercise intolerance. JACC Heart Fail. 2016;4:636–645.

18. Haykowsky MJ, Brubaker PH, John JM, Stewart KP, Morgan TM, Kitzman DW. Determinants of exercise intolerance in elderly heart failure patients with preserved ejection fraction. J Am Coll Cardiol. 2011;58:265–274.

19. Dhakal BP, Mahnorta R, Murphy RM, Pappagianopoulos PP, Baggish AL, Weiner RB, Houstis NE, Eisman AS, Hough SS, Lewis GD. Mechanisms of exercise intolerance in heart failure with preserved ejection fraction: the role of abnormal peripheral oxygen extraction. Circ Heart Fail. 2015;8:286–294.

20. Kitzman DW, Nicklas B, Kraus WE, Lyles MF, Egggebeen J, Morgan TM, Haykowsky M. Skeletal muscle abnormalities and exercise intolerance in older patients with heart failure and preserved ejection fraction. Am J Physiol Heart Circ Physiol. 2014;306:H1364–H1370.

21. Borlaug BA, Kote GC, Melenovsky V, Olson TP. Abnormal right ventricular-pulmonary artery coupling with exercise in heart failure with preserved ejection fraction. Eur Heart J. 2016;37:3302–3302.

22. Bhella PS, Pacini EL, Prasad A, Hastings JL, Adams-Huet B, Thomas JD, Grayburn PA, Levine BD. Echocardiographic indices do not reliably track changes in left-sided filling pressure in healthy subjects or patients with heart failure with preserved ejection fraction. Circ Cardiovasc Imaging. 2011;4:482–489.

23. Abudim MM, Redfield MM, Melenovsky V, Olson TP, Kass DA, Johnson BD, Borlaug BA. Cardiac output response to exercise in relation to metabolic demand in heart failure with preserved ejection fraction. Eur J Heart Fail. 2013;15:776–785.

24. Shah SJ, Kuzh DH, Selvaraj S, Burke MA, Yancy CW, Gheorghiade M, Bonow RO, Huang C-C, Deo RC. Phenomapping for novel classification of heart failure with preserved ejection fraction. J Appl Physiol. 2014;129:239–2350.

25. Hepple RT, Mackinnon SLM, Goodman JM, Thomas SG, Pyhely MJ. Resistance and aerobic training in older men: effects on VO2 peak and the capillary supply to skeletal muscle delivery. J Appl Physiol. 1997;82:1305–1310.

26. Pu CT, Johnson MT, Forman DE, Hausdorff JM, Roubenoff R, Fielding RA, Singh MA. Randomized trial of progressive resistance training to counteract the myopathy of chronic heart failure. J Appl Physiol. 2001;90:2341–2350.

27. Borlaug BA, Olson TP, Lam CSP, Flood KS, Lerman A, Johnson BD, Redfield MM. Global cardiovascular reserve dysfunction in heart failure with preserved ejection fraction. J Am Coll Cardiol. 2010;56:845–854.